NCT05509985 - A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

September 9, 2023

Study Completion Date

September 9, 2024

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

ASKG315

Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.

Trial Locations (2)

The Alfred Hospital, Melbourne

Blacktown Hospital, Sydney